drug
dronedarone hydrochloride
Marketedupdated 3mo agoby Sanofi-Aventis US LLC
Approvedcommunity read0 votes
indications
investigational
Atrial Fibrillation
all catalysts(0)
nothing on the calendar yet
Trials studying dronedarone hydrochloride
Patent cliff
source: FDA Orange Bookfirst barrier falls
Apr 16, 2029
~2.7 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (3)
- Jun 30, 2031method-of-use (U-1473)US 86022154.9y
- Apr 16, 2029method-of-use (U-1388)US 84101672.7y
- Apr 16, 2029method-of-use (U-1726)US 91079002.7y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 8m ago
Found something off?
comments(0)
5-min edit window · permanent after that